KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Charles River Laboratories International (CRL) EBT (2016 - 2025)

Charles River Laboratories International has reported EBT over the past 17 years, most recently at -$294.1 million for Q4 2025.

  • For Q4 2025, EBT fell 35.66% year-over-year to -$294.1 million; the TTM value through Dec 2025 reached -$99.5 million, down 206.86%, while the annual FY2025 figure was -$99.5 million, 206.86% down from the prior year.
  • EBT for Q4 2025 was -$294.1 million at Charles River Laboratories International, down from $87.2 million in the prior quarter.
  • Over five years, EBT peaked at $244.9 million in Q4 2022 and troughed at -$294.1 million in Q4 2025.
  • A 5-year average of $83.9 million and a median of $116.3 million in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: soared 67.18% in 2022 and later plummeted 203.87% in 2024.
  • Year by year, EBT stood at $163.6 million in 2021, then soared by 49.67% to $244.9 million in 2022, then dropped by 14.79% to $208.7 million in 2023, then plummeted by 203.87% to -$216.8 million in 2024, then crashed by 35.66% to -$294.1 million in 2025.
  • Business Quant data shows EBT for CRL at -$294.1 million in Q4 2025, $87.2 million in Q3 2025, and $71.4 million in Q2 2025.